Mkts

Immunovant, Inc.

NASDAQ: IMVT
$28.59+0.97 (+3.51%)
As of Oct 20, 4:00 PM ET

Key statistics

Day range
27.6229.14
52-week range
17.0245.42
Today
Open27.76
Previous close28.59
Volume1.24M
Valuation
Market cap5.92B
P/E ratio—
EPS (TTM)-2.81
Income & risk
Dividend / yield—
Beta0.93
Avg volume1.36M
Discussion

IMVT News

Stories mentioning IMVT from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development
Sales General & Admin
Total Operating Expenses159,554114,362131,762127,224113,826114,302115,74394,281
Operating Income (Loss)
Interest Income
Interest Expense
Other Expense798.00(54.00)250.001,1871,072(1,258)629.0028.00
Pretax Income(150,700)(109,083)(125,908)(119,700)(105,865)(110,970)(109,041)(87,073)
Tax Provision(2,844)1,552594.00913.00584.00152.0078.0077.00
Net Income (Loss)(147,856)(110,635)(126,502)(120,613)(106,449)(111,122)(109,119)(87,150)
Earnings Per Share (Basic)(0.81)(0.61)(0.73)(0.71)(0.70)(0.76)(0.74)(0.60)
Earnings Per Share (Diluted)(0.81)(0.61)(0.73)(0.71)(0.70)(0.76)(0.74)(0.60)
Weighted Average Shares Outstanding (Basic)182,421181,513173,644170,873151,574146,922146,469146,086
Weighted Average Shares Outstanding (Diluted)182,421181,513173,644170,873151,574146,922146,469146,086

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About IMVT

Immunovant, Inc. (NASDAQ: IMVT) is a stock listed on the Nasdaq Stock Market under the ticker symbol IMVT. It last traded at $28.59 (Oct 20, 2026, 4:00 PM ET), up 3.5% on the day. That gives Immunovant a market capitalisation of $5.9B.

Over the past 52 weeks IMVT has traded between $17.02 and $45.42.

For the quarter ended Mar 31, 2026 it reported a net loss of $147.9M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$147.9M
Dec 31, 2025—-$110.6M
Sep 30, 2025—-$126.5M
Jun 30, 2025—-$120.6M

From Immunovant’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…